Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Julie Hejl; Klaus Theede; Brian Møllgren; Kirsten Vikkelsø Madsen; Ashraf Heidari; Anna á Steig; Mogens Fenger

doi:https://doi.org/10.1016/j.plabm.2017.11.002

Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Bidragets oversatte titel: Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Julie Hejl, Klaus Theede, Brian Møllgren, Kirsten Vikkelsø Madsen, Ashraf Heidari, Anna á Steig, Mogens Fenger

Publikation: Bidrag til tidsskrift › Tidsskriftsartikel › Forskning › peer review

Abstract

Objectives

Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration.

Design and methods

Fifty-five stool samples were analyzed by the IBDoc® Calprotectin Home Testing kit and the BÜHLMANN fCAL® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated.

Results

We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (BÜHLMANN fCAL® turbo) and in the range of 4.8–26.6% (IBDoc®).

Conclusions

This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

Bidragets oversatte titel	Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis
Originalsprog	Engelsk
Tidsskrift	Practical Laboratory Medicine
Vol/bind	10
Sider (fra-til)	10-14
Antal sider	5
ISSN	2352-5517
DOI	https://doi.org/10.1016/j.plabm.2017.11.002
Status	Udgivet - mar. 2018

Emneord

Kliniske undersøgelsesmetoder, laboratorieteknologi og radiografi
Sygdom, sundhedsvidenskab og sygepleje

Adgang til dokumentet

https://doi.org/10.1016/j.plabm.2017.11.002

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{39cec1f0b9824081b638d2a6312fe9f2,

title = "Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis",

abstract = "Objectives Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods Fifty-five stool samples were analyzed by the IBDoc {\textregistered} Calprotectin Home Testing kit and the B{\"U}HLMANN fCAL {\textregistered} turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated. Results We found a strong correlation coefficient of 0.887 between FC measured on IBDoc{\textregistered} and the laboratory assay B{\"U}HLMANN fCAL {\textregistered} turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (B{\"U}HLMANN fCAL {\textregistered} turbo) and in the range of 4.8–26.6% (IBDoc {\textregistered}). Conclusions This study suggests that IBDoc{\textregistered} is a suitable alternative for the assessment of disease activity in IBD patients.",

keywords = "clinical assessment methods, lab technology and radiography, disease, health science and nursing",

author = "Julie Hejl and Klaus Theede and Brian M{\o}llgren and Madsen, {Kirsten Vikkels{\o}} and Ashraf Heidari and {{\'a} Steig}, Anna and Mogens Fenger",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors",

year = "2018",

month = mar,

doi = "https://doi.org/10.1016/j.plabm.2017.11.002",

language = "English",

volume = "10",

pages = "10--14",

journal = "Practical Laboratory Medicine",

issn = "2352-5517",

publisher = "Elsevier",

}

TY - JOUR

T1 - Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

AU - Hejl, Julie

AU - Theede, Klaus

AU - Møllgren, Brian

AU - Madsen, Kirsten Vikkelsø

AU - Heidari, Ashraf

AU - á Steig, Anna

AU - Fenger, Mogens

PY - 2018/3

Y1 - 2018/3

N2 - Objectives Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods Fifty-five stool samples were analyzed by the IBDoc ® Calprotectin Home Testing kit and the BÜHLMANN fCAL ® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated. Results We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL ® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (BÜHLMANN fCAL ® turbo) and in the range of 4.8–26.6% (IBDoc ®). Conclusions This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

AB - Objectives Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods Fifty-five stool samples were analyzed by the IBDoc ® Calprotectin Home Testing kit and the BÜHLMANN fCAL ® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated. Results We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL ® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (BÜHLMANN fCAL ® turbo) and in the range of 4.8–26.6% (IBDoc ®). Conclusions This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

KW - clinical assessment methods, lab technology and radiography

KW - disease, health science and nursing

UR - http://www.scopus.com/inward/record.url?scp=85037116596&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.plabm.2017.11.002

DO - https://doi.org/10.1016/j.plabm.2017.11.002

M3 - Journal article

SN - 2352-5517

VL - 10

SP - 10

EP - 14

JO - Practical Laboratory Medicine

JF - Practical Laboratory Medicine

ER -

Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater